Allogeneic bone marrow transplantation in XXXX : report from the European Cooperative Group for bone marrow transplantation (8 cases).

@entity1 @entity6113 @entity1072 @entity5805 @entity205 @entity2132 @entity1499 @entity1779
Allogenic bone marrow transplantation (BMT) was performed in 8 @entity1 with B @entity1072 ( @entity1072 ): 6 males and 2 females with a median age of 41 years (37 to 46). Seven @entity1 were resistant to previous therapy and were grafted in the evolutive phase. Only 1 @entity1 was grafted without any previous treatment. At the time of BMT 5 @entity1 were classified according to the Rai classification in stage IV, 1 in stage III and 2 in stage 1. The delay between diagnosis and BMT was 47 months (5 to 68). @entity2132 ( @entity2132 ) prophylaxis was methotrexate (1 @entity1 ), @entity205 (2 @entity1 ), @entity1499 + @entity205 (3 @entity1 ), @entity205 + physical removal of T cells (2 @entity1 ). The conditioning regimen was standard for 5 @entity1 , reinforced for 3 @entity1 with @entity5805 (1 @entity1 ) and etoposide (2 @entity1 ). A successful engraftment was obtained in all cases. The @entity6113 decreased slowly and disappeared from day 0 to day 28. All @entity1 developed an acute @entity2132 5 of which resolved. Three @entity1 died: 2 of acute @entity2132 and 1 of @entity1779 . Five @entity1 are alive in persistent complete remission without clinical symptoms and with normal peripheral blood and normal bone marrow. The median follow-up is 27 months (13-53). This small series suggests that allogeneic BMT should be investigated in selected @entity1 as possible curative treatment of @entity1072 .
